Allan Tindikahwa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Allan Tindikahwa has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Betty Mwesigwa
Makerere University Walter Reed Program, Kampala P.O. Box 16524, Uganda
1 shared publication - Ezra Musingye
Makerere University Walter Reed Program, Plot 42 Nakasero Rd, Kampala P.O. Box 16524, Uganda
1 shared publication - Fred Wabwire-Mangen
Makerere University Walter Reed Project, Kampala P.O. Box 16524, Uganda
1 shared publication - Grace Mirembe
Makerere University Walter Reed Program, Plot 42 Nakasero Rd, Kampala P.O. Box 16524, Uganda
1 shared publication - Hannah Kibuuka
Makerere University-Walter Reed Program, Kampala, Uganda
1 shared publication - Jude Thaddeus Ssensamba
Makerere University Walter Reed Project, Kampala, Uganda
1 shared publication
Latest Publications
- Open Access
- 26 August 2022
- Published by African Journals Online (AJOL) in African Health Sciences
- Vol. 22 (2) , 34-41.
Developing capacity for implementation and evaluation of vaccine trials in Uganda: Perspective of the Makerere University Walter Reed Project
Introduction: Infectious diseases and neglected tropical diseases continue to be a major challenge in resource limited settings, causing significant morbidity and mortality. Although vaccines are a key biomedical prevention tool, resource limited settings often lack the infrastructure, regulatory frameworks, and skilled human resource to conduct vaccine clinical trials. To address this gap, the Makerere University Walter Reed Project (MUWRP) was established and has contributed to vaccine research in Uganda and globally. Methods: This was achieved through training a strong vaccine clinical trial workforce; development of requisite clinical trial infrastructure for research activities and management of investigational products; conducting phase I-III vaccine trials and contribution to national ethical and regulatory frameworks that protect participants. Results: As of 2022, MUWRP had successfully conducted and completed five phase I/II HIV vaccine clinical trials, five for Ebola and Marburg, while one phase I/II Schistosomiasis and one phase III COVID-19 vaccine clinical trial are ongoing. Discussion: The completed vaccine trials provided critical scientific knowledge on the safety and immunogenicity of investigational products which informed the design of better vaccines for diseases of global health importance. Conclusion: Academia, through establishment of appropriate partnerships can contribute to the identification of solutions to complex public health challenges. Keywords: Vaccines; community participation; developing countries.
- 26 August 2022
- Published by African Journals Online (AJOL) in African Health Sciences
- Vol. 22 (2) , 34-41.
Open AccessDeveloping capacity for implementation and evaluation of vaccine trials in Uganda: Perspective of the Makerere University Walter Reed Project
Introduction: Infectious diseases and neglected tropical diseases continue to be a major challenge in resource limited settings, causing significant morbidity and mortality. Although vaccines are a key biomedical prevention tool, resource limited settings often lack the infrastructure, regulatory frameworks, and skilled human resource to conduct vaccine clinical trials. To address this gap, the Makerere University Walter Reed Project (MUWRP) was established and has contributed to vaccine research in Uganda and globally. Methods: This was achieved through training a strong vaccine clinical trial workforce; development of requisite clinical trial infrastructure for research activities and management of investigational products; conducting phase I-III vaccine trials and contribution to national ethical and regulatory frameworks that protect participants. Results: As of 2022, MUWRP had successfully conducted and completed five phase I/II HIV vaccine clinical trials, five for Ebola and Marburg, while one phase I/II Schistosomiasis and one phase III COVID-19 vaccine clinical trial are ongoing. Discussion: The completed vaccine trials provided critical scientific knowledge on the safety and immunogenicity of investigational products which informed the design of better vaccines for diseases of global health importance. Conclusion: Academia, through establishment of appropriate partnerships can contribute to the identification of solutions to complex public health challenges. Keywords: Vaccines; community participation; developing countries.